Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer ...Middle East

SAN FRANCISCO and SUZHOU,China, April 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and...

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer )

Also on site :

• Padres Release Jason Heyward
• UNHCR: 2.5M refugees need resettlement as US freezes program
• Adidas Has 'Sleek' $180 Running Shoes for Just $90, and Reviewers Say They Feel Like They’re 'Walking On Clouds'